CERVOMED INC. - COMMON

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

02 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

25 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

17 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

10 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

31 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Present at the 8th International Lewy Body Dementia Conference

29 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

27 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Key Senior Leadership Appointments

13 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08 Nov 2024 09:55:32 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

07 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

29 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

27 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire